Economy/Home · Economy

[Breaking] AptaBio Receives Phase 2 Topline Data for Kidney Injury Treatment 'Isuzinaxib (APX-115)'... Safety Confirmed, Final Report Expected in First Half of 2027

AptaBio announced in a regulatory filing on the 14th that it has received Phase 2 topline data for 'Isuzinaxib (APX-115)', a treatment for contrast-induced acute kidney injury (CI-AKI), and confirmed its safety. ■ Safety Secured in Both Treatment and Placebo Groups According to the safety analysis

Oseong Kwon
Staff Reporter
5 min read
[Breaking] AptaBio Receives Phase 2 Topline Data for Kidney Injury Treatment 'Isuzinaxib (APX-115)'... Safety Confirmed, Final Report Expected in First Half of 2027
CBC News

AptaBio announced in a regulatory filing on the 14th that it has received Phase 2 topline data for 'Isuzinaxib (APX-115)', a treatment for contrast-induced acute kidney injury (CI-AKI), and confirmed its safety.

■ Safety Secured in Both Treatment and Placebo Groups

According to the safety analysis results of this clinical trial, no clinically significant abnormal findings were observed in either the APX-115 treatment group or the placebo group. The company explained that no clinically significant safety-related changes were observed in adverse reactions, physical examinations, electrocardiograms, pulse measurements, or clinical laboratory tests, confirming the safety of APX-115 administration.

Notably, the company stated that no safety concerns were identified even in the high-risk trial group with reduced renal function, defined as an estimated glomerular filtration rate (eGFR) of 45mL/min/1.73㎡ or below.

■ How the Phase 2 Trial Was Designed

This clinical trial was conducted to evaluate the safety of orally administered APX-115 compared to placebo in patients undergoing percutaneous coronary intervention (PCI).

It is a Phase 2 trial approved by the U.S. Food and Drug Administration (FDA) and Korea's Ministry of Food and Drug Safety (MFDS), conducted as a multinational, multi-center, randomized, double-blind, placebo-controlled study at 14 hospitals in Korea and the United States.

A total of 230 subjects were planned for randomization, with 160 evaluable planned subjects undergoing PCI. The dosing period was set at five days. The primary endpoint is a safety assessment over 12 weeks, including adverse reactions, hematology, blood chemistry, urinalysis, physical examinations, vital signs, and electrocardiograms. The last visit date of the final subject was July 22 of this year.

■ Partial Efficacy Data to Be Presented at ASN 2026... Final Report Targeted for First Half of 2027

AptaBio plans to present some of the efficacy results from this Phase 2 trial at the 'Late-Breaking Oral Session' of the American Society of Nephrology (ASN 2026), an international academic conference. The final clinical trial results report is expected to be secured by the first half of 2027.

Meanwhile, October 14, the date of the reported event, is when AptaBio received the topline data from its contract research organization (CRO).

■ Investment Cautions Also Disclosed

Through its investment caution disclosures, the company noted that the probability of an investigational drug receiving final regulatory approval is known to be statistically around 10%, and that commercialization plans may be changed or abandoned depending on the results of future clinical trials and the approval process.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.